PM360

JULY 13, 2023

PM360 asked experts in helping patients stay on their prescribed therapies about where the industry could make the biggest improvements and how to better detect potential barriers. How can the industry better monitor and detect potential barriers to adherence for individual patients? How can they improve?

Patients 98

Patients Medical Education Transportation 98

pharmaphorum

JANUARY 24, 2023

Pharma will be focusing more on relevant research, support, and a better mix of non-promotional and promotional interaction. Given the funding environment for innovative medicines that is faced by all pharma, large or small, once assets are approved, however, this 2023 reset seems a necessary response.

Medicine 92

Medicine Healthcare Healthcare Pharma 92

PM360

AUGUST 9, 2022

The industry has been limited in its ability to implement creative solutions to engage and motivate patients because the FDA has strict guidelines for what pharma companies can communicate with patients. Today, we still can’t easily discern whether a patient took their pill or not and the reason why. Michael Oleksiw.

Medical 105

Medical Electronics Patients Healthcare 105

European Pharmaceutical Review

JANUARY 25, 2024

Within the EU, patient information leaflets (PILs) are not merely a regulatory requirement but a cornerstone of patient safety. It emphasises its ability to make information interoperable with electronic health systems such as e-prescription and electronic health records.

Healthcare 79

Healthcare Healthcare Electronics Safety 79

Clarify Health

OCTOBER 26, 2021

By enrolling participants with a wide range of baseline characteristics, study populations will more accurately reflect the patients likely to take the drug if it is approved. Cancer patients treated in clinical trials live substantially longer than those not treated in trials and benefit from lower hospital readmissions. 2] Figure 1.

Food and Drug Administration 52

Food and Drug Administration Recruitment Pharmaceutical manufacturing Medical 52

Clarify Health

MAY 19, 2020

The time-consuming and resource-intensive path from the lab bench to the patient bedside starts with drug discovery, progresses to pre-clinical and clinical research, and then enters regulatory review. Any misstep in terms of pricing, reimbursement, or marketing could mean delays in providing therapies to the patients who need them most.

Biopharma 52

Biopharma Physicians Marketing Prescription 52

Clarify Health

APRIL 1, 2021

Many healthcare and life sciences organizations recognize the impact of top social determinants of health on outcomes and cost, prompting them to invest in programs to address the non-clinical factors in patients’ lives. A study in Health Affairs estimates that health systems have invested at least $2.5

Healthcare 52

Healthcare Healthcare Transportation Patients 52

Clarify Health

DECEMBER 13, 2022

Less than four percent of Americans participate in clinical studies; 30 percent of patients drop out; and 80 percent of studies do not meet enrollment deadlines. Dr. Rizk provided an example of how we’re getting better at meeting patients where they are. Below are highlights and key takeaways from the panel.

Recruitment 52

Recruitment Retail Patients Education 52

Clarify Health

DECEMBER 13, 2022

Less than four percent of Americans participate in clinical studies; 30 percent of patients drop out; and 80 percent of studies do not meet enrollment deadlines. Dr. Rizk provided an example of how we’re getting better at meeting patients where they are. Below are highlights and key takeaways from the panel.

Recruitment 52

Recruitment Retail Patients Education 52